- By ICR Secretariat
- Posted Tuesday, November 29, 2022
Infex begins study of pseudomonas aeruginosa candidate RESP-X
https://www.pharmatimes.com/news/infex_begins_study_of_pseudomonas_aeruginosa_candidate_resp-x_1481257
Phase 1 research will evaluate tolerability and safety of therapy among healthy volunteers
Infex – a company focusing on anti-infectives specialist – has announced that the first patients have been dosed in its phase 1 study researching candidate RESP-X.
The oldest independent membership-led professional body for clinical researchers across the globe.
Latest Posts
- 10 clinical trials to watch in the first half of 2023 19/01/2023 03:56 PM
- 'The Top Line': FDA's stance on cancer drug approval, plus this week's headlines 19/01/2023 03:55 PM
- 5 questions facing gene therapy in 2023 19/01/2023 03:53 PM
Useful Links
Contact Us
Suite 11a, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org